Health Canada clears Devonian to start pediatric Phase II/III Thykamine atopic dermatitis trial

• Health Canada cleared Devonian Health Group to start a Phase II/III pediatric trial of Thykamine cream for mild-to-moderate atopic dermatitis.
• Study targets patients aged 3 months to 17 years, using a seamless adaptive design with an interim analysis to move into Phase III.
• About 306 patients planned, testing 0.05% and 0.1% Thykamine versus placebo over 12 weeks of twice-daily dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Devonian Health Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607210845PR_NEWS_USPR_____MO08426) on July 21, 2026, and is solely responsible for the information contained therein.